CO2023002650A2 - Formas farmacéuticas sólidas de palbociclib - Google Patents

Formas farmacéuticas sólidas de palbociclib

Info

Publication number
CO2023002650A2
CO2023002650A2 CONC2023/0002650A CO2023002650A CO2023002650A2 CO 2023002650 A2 CO2023002650 A2 CO 2023002650A2 CO 2023002650 A CO2023002650 A CO 2023002650A CO 2023002650 A2 CO2023002650 A2 CO 2023002650A2
Authority
CO
Colombia
Prior art keywords
palbociclib
dosage forms
solid dosage
pharmaceutical compositions
relates
Prior art date
Application number
CONC2023/0002650A
Other languages
English (en)
Inventor
Balakrishnan Bithunshal Usha
Ramdas Manakkote
Varma Srinivasa Rajasekara Rudraraju
Original Assignee
Aizant Drug Res Solutions Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aizant Drug Res Solutions Private Limited filed Critical Aizant Drug Res Solutions Private Limited
Publication of CO2023002650A2 publication Critical patent/CO2023002650A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevas composiciones farmacéuticas que comprenden palbociclib, como compuesto farmacéuticamente activo. Específicamente, la presente invención se refiere a formas de dosificación sólidas de palbociclib que comprenden al menos un compuesto seleccionado del grupo que consiste en aminoácidos o péptidos que contienen azufre, y al menos una vitamina que tiene propiedades antioxidantes. Las formas de dosificación descritas en la presente son preparaciones orales químicamente estables que tienen características farmacocinéticas y propiedades de disolución deseables. La invención también se dirige al uso de dichas composiciones farmacéuticas como medicamento, en particular para el tratamiento del cáncer.
CONC2023/0002650A 2020-08-05 2023-03-02 Formas farmacéuticas sólidas de palbociclib CO2023002650A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041033503 2020-08-05
PCT/IN2021/050746 WO2022029799A1 (en) 2020-08-05 2021-08-03 Solid dosage forms of palbociclib

Publications (1)

Publication Number Publication Date
CO2023002650A2 true CO2023002650A2 (es) 2023-06-20

Family

ID=77821971

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0002650A CO2023002650A2 (es) 2020-08-05 2023-03-02 Formas farmacéuticas sólidas de palbociclib

Country Status (7)

Country Link
US (1) US20230263734A1 (es)
EP (1) EP4192439A1 (es)
BR (1) BR112023002161A2 (es)
CA (1) CA3190856A1 (es)
CO (1) CO2023002650A2 (es)
MX (1) MX2023001572A (es)
WO (1) WO2022029799A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4302755A1 (en) * 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004090B1 (en) * 2013-05-28 2017-10-25 Astrazeneca AB Chemical compounds
WO2016156070A1 (en) * 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib

Also Published As

Publication number Publication date
WO2022029799A1 (en) 2022-02-10
BR112023002161A2 (pt) 2023-04-04
EP4192439A1 (en) 2023-06-14
CA3190856A1 (en) 2022-02-10
MX2023001572A (es) 2023-05-08
US20230263734A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
AR124482A2 (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
ECSP17034829A (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
AR107014A1 (es) Formulación farmacéutica acuosa
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
GT201200069A (es) Formulaciones farmacéuticas muy concentradas
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
CL2018003178A1 (es) Composición farmacéutica
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
UY27378A1 (es) Composición farmacéutica
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
UY38069A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO6640318A2 (es) Formas de dosificación oral de bendamustina
CL2021001018A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
ECSP21043639A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
UY38982A (es) Composiciones farmacéuticas
EA201500710A1 (ru) Фармацевтическая композиция для лечения вич-инфекций
AR108792A1 (es) Composiciones que comprenden timolol
AR125470A1 (es) Composición farmacéutica de pembrolizumab y su uso
CR20180014A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos